Navigation Links
Early Detection of MS Treatment Complication May Improve Survival
Date:3/10/2013

SAN DIEGO, March 10, 2013 /PRNewswire-USNewswire/ -- The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels.

The study examined 319 people with MS who were treated with natalizumab and diagnosed with PML. Because of the risk of PML, people taking natalizumab are monitored by their physicians for possible symptoms of the brain infection. The study compared people who had symptoms of PML at the time of  diagnosis to people who had  no symptoms of the infection, but who were diagnosed with the disease by brain scans and tests in the spinal fluid for the virus that causes the infection. The level of disability for the people in the study was assessed before the PML diagnosis, at the time of diagnosis, and again six months and one year after the diagnosis.

A total of 21 people had no PML symptoms at the time of their diagnosis, while 298 people had symptoms. The preliminary data from the study suggest that people who have no symptoms at diagnosis may have improved survival and less disability than those who had developed symptoms prior to their diagnosis, according to study author Tuan Dong-Si , MD, a medical director with Biogen Idec in Weston, MA.

At the time of PML diagnosis, those people with no symptoms had an average score of 67 on the Karnofsky Performance Scale, which measures disability, while those people with symptoms had a score of 54. A Karnofsky score of 70 indicates that the individual may be able to care for him or herself, but may be unable to carry on normal activities or do active work. A Karnofsky score of 50 indicates that a person may require considerable assistance and frequent medical care. One year after PML diagnosis, the average Karnofsky score of those people with no symptoms at diagnosis was 70, compared to 47 for those with symptoms at diagnosis. Karnofsky scores of less than 50 indicate that the individual may be unable to care for him or herself and may require institutional care or the equivalent.

As of January 1, 2013, all of the 21 people (100 percent) with no symptoms at the time of PML diagnosis were living, compared to 77 percent of the people with symptoms at the time of diagnosis.  "These results suggest that the consequences of PML infection can be mitigated by early detection of the disease," said Dong-Si.

Natalizumab is generally prescribed for people who have not responded to or cannot tolerate other treatments for MS.

The study was supported by Biogen Idec Inc. and Elan Pharmaceuticals.

Learn more about multiple sclerosis at http://www.aan.com/patients.

The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.

 


'/>"/>
SOURCE American Academy of Neurology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
2. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
3. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
6. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
7. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
8. joimax® at the Early Summer Congresses: SpineWeek Amsterdam and DGNC Leipzig
9. Senate to Vote on Final FDA User Fee Bill As Early As Today
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. CIVCO Showcases "Clearly Different" Products at AAPM 2012 Booth #217
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
(Date:2/23/2017)... Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... innovative proprietary products for the urology market, will release ... ended December 31, 2016 before the market open on ... will host a conference call and webcast to discuss ... 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs ... benchmarks in the global Oesophageal Cancer market. The research ... the key drugs marketed for Oesophageal Cancer and their clinical attributes? ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 2017 , ... Functional imaging data supports improved cognition in ... today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , It ... improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et al., ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist ... his office, Antoine Dental Center. Currently, patients can get single dental implants for ... but patients can learn more about these offers by contacting Antoine Dental Center. ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provost of Liberty University, has officially announced the appointment of Peter A. Bell, ... College of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to ...
(Date:2/24/2017)... ... 24, 2017 , ... Healthcare Associates of McKinney announced today that ... at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in ... , As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):